Inhaled interferons beta and SARS-COV2 infection: a preliminary therapeutic perspective.
Expert Rev Respir Med
; 16(3): 257-261, 2022 03.
Article
in English
| MEDLINE | ID: covidwho-1522052
ABSTRACT
INTRODUCTION:
SARS-COV2 infection represents a therapeutic challenge due to the limited number of effective therapies available and due to the fact that it is not clear which host response in terms of inflammation pattern is the most predictive for an optimal (and rapid) recovery. Interferon ß pathway is impaired in SARS-COV2 infection and this is associated with a bigger disease burden. Exogenous inhaled interferon might be beneficial in this setting. AREAS COVERED Nebulized interferon-ß is currently investigated as a potential therapy for SARS-COV2 because the available data from a phase II study demonstrate that this medication is able to accelerate the recovery from disease. EXPERT OPINION Further clinical studies are needed in order to better document the efficacy of this therapy especially in severe forms of COVID-19, the optimal duration of therapy and if such a medication is appropriate for domiciliary use. Also combined regimens with antivirals or with compounds which are able to enhance the endogenous production of interferon might be of promise.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Interferons
/
COVID-19 Drug Treatment
Type of study:
Prognostic study
Limits:
Humans
Language:
English
Journal:
Expert Rev Respir Med
Year:
2022
Document Type:
Article
Affiliation country:
17476348.2022.2008910
Similar
MEDLINE
...
LILACS
LIS